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Metastatic RCC with 38,000 new cases diagnosed in the United States every year is notori-
ously resistant to conventional chemotherapy and is almost invariably an incurable condi-
tion. New biologic drugs are beginning to break this resistance, reflecting in the registration
of four innovative agents for treatment of advanced RCC in the last 2 years, bevacizumab,
sorafenib, sunitinib and temsirolimus. Small-molecule multikinase inhibitors targeting
VEGF receptors (sunitinib and sorafenib) can prolong time to progression and preserve
quality of life when used in newly diagnosed or previously treated patients. The anti-VEGF
antibody bevacizumab enhances response rate and prolongs disease control when added to
interferon. Temsirolimus, mammalian target of rapamycin inhibitor, prolongs the survival
duration of patients with poor-risk disease. In this review, we report pre-clinical data, data
relative to registrative phase III trials, and guideline indications for an optimal use of these
new agents that are revolutionising the management of metastatic Renal Cell Carcinoma.
 2008 Elsevier Ltd. All rights reserved.Metastatic RCC with 38,000 new cases diagnosed in the ysis showed that there was no significant survivalUnited States (US) every year1 is notoriously resistant to con-
ventional chemotherapy, and is almost invariably an incurable
condition. However, new biologic drugs are beginning to break
this resistance, reflecting in the registration of four innovative
agents for the treatment of advanced RCC in the last 2 years,
bevacizumab, sorafenib, sunitinib and temsirolimus.
1. Bevacizumab
One-half of clear-cell RCCs have upregulation of HIF-1/2 and
HIF target genes including VEGF.2 Bevacizumab, a humanised
recombinant anti-VEGF antibody, binds all types of VEGF-A
isoforms and neutralises their activities.3 A phase III trial
involving 641 patients with metastatic clear-cell RCC com-
pared IFN combined with either bevacizumab or placebo. Bev-
acizumab resulted in a significantly longer progression-free
survival (PFS) time (10.2 versus 5.4 months) and higher objec-
tive tumour response rate (30.6% versus 12.4%). Interim anal-er Ltd. All rights reserved
m (G. Cartenı`).advantage. Common toxicities seen in this trial were hyper-
tension, proteinuria, bleeding and thrombotic events.4
2. Multikinase inhibitors
Small-molecule kinase inhibitors that havemore than one tar-
get (multikinase inhibitors) aregenerating considerable excite-
ment in the treatment of metastatic RCC. Sequencing of the
humangenomehas identified518 putativekinases, 90 tyrosine
kinases and 58 receptor tyrosine kinases.5Moreover, the in vivo
targets are likely to include kinases present in both the tumour
cells and stroma (e.g. endothelial cells). Because deregulation
of HIF is an important aspect of RCC development, agents that
affect HIF target genes, especially those encoding VEGF and
VEGF receptors (VEGFRs), may be particularly useful. Two such
VEGFR inhibitors, sorafenib and sunitinib malate, demon-
strated sufficient activity to receive regulatory approval for
their use in mRCC in the US and Europe..
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Sorafenib was initially found in a screen for agents to block
the Raf proteins C-Raf and B-Raf. Further examination
demonstrated that this compound also blocked other kinases,
including VEGFR-2 and VEGFR-3, platelet-derived growth fac-
tor receptor (PDGF), as well as the receptors for Flt-3 ligand
and stem cell factor.6,7
Signalling through many receptors involves the activation
of Ras, recruitment of Raf to the membrane and subsequent
activation of the mitogen-activated protein kinase (MAPK)–
extracellular signal–related kinase (ERK) pathway, which af-
fects a large number of downstream cellular responses. In vitro
sorafenib is a potent inhibitor of ERK phosphorylation in
many, but not all, cancer cell lines. In particular, cell lineswith
activating mutations of KRAS appear non-responsive. How-
ever, in vivo growth of these resistant cell lines could still be
inhibited by sorafenib, suggesting an antiangiogenic effect.7
The role of sorafenib in RCC was solidified in the Treat-
ment Approaches in Renal Cancer Global Evaluation Trial
(TARGET) study, in which 903 patients with cytokine-refrac-
tory metastatic clear-cell RCC of low or intermediate risk,
according to the MSKCC classification,8 were randomised to
receive sorafenib or placebo. Median PFS times were 5.5
months in the sorafenib group and 2.8 months in the placebo
group, and objective response rates were 10% in sorafenib
arm and 2% in placebo arm. Although the difference in sur-
vival favoring sorafenib was not statistically significant, it
may have been because of early crossover allowed shortly
after an interim analysis showing a difference in PFS. That
trial also characterised the side-effect profile of sorafenib.
Discontinuation of treatment because of side-effects occurred
in 10% of patients receiving sorafenib, and 13% required dose
reductions for toxicity. The most important side-effects were
diarrhoea, hypertension, skin rash, and hand–foot syn-
drome.9 With the observed benefit of sorafenib in patients
refractory to first-line therapy (mostly immunotherapy) from
the TARGET trial, sorafenib was compared with IFN in un-
treated patients in a randomised phase II trial. Objective re-
sponse rate was only 5% in patients receiving sorafenib,
with no advantage over IFN in terms of response rate or PFS
duration (5.7 versus 5.6 months).10 However, from the large
sorafenib open-access programme, there were 224 previously
untreated patients for whom the PFS duration was 35
weeks.11
2.2. Sunitinib
Sunitinib malate is also an oral multikinase inhibitor that
blocks the activity of VEGFR-2 and PDGFR, as well as Src,
Abl, insulin-like growth factor receptor-1 and fibroblast
growth factor receptor-1 tyrosine kinases.12 Its effect on RCC
became evident with the results of two multi-institutional
phase II trials enrolling patients previously treated predomi-
nantly with immunotherapy. The first study, including 63 pa-
tients with various histologies (the large majority had clear-
cell carcinoma) of RCC, demonstrated a 40% objective re-
sponse rate and median time to progression (TTP) of 8.7
months.13 The second study required prior nephrectomy
and included 106 previously treated patients whose tumourswere predominantly of the clear-cell type, with a response
rate of 34% and median disease-free survival interval of 8.3
months.14 Despite the broad overlap of targeted kinases be-
tween sunitinib and sorafenib, sunitinib has a distinct profile
of side-effects, predominantly leukopaenia, thrombocytopae-
nia, stomatitis and transient skin discoloration, with skin
rash and diarrhoea being less frequent. The remarkable activ-
ity of sunitinib seen in patients with refractory disease justi-
fied a large multi-institutional phase III trial randomizing 750
previously untreated patients with RCC with a clear-cell com-
ponent to receive sunitinib or IFN. A higher objective response
rate was seen in sunitinib arm (31% versus 6%), as were a
longer PFS time (11 versus 5 months) and better quality of life.
Interestingly, the benefit of sunitinib was demonstrated in all
MSKCC risk groups. At last interim analysis, 13% of the pa-
tients had died in sunitinib arm versus 17% in IFN arm but
this is not still significant.15 As a result, sunitinib has emerged
as the predominant first-line treatment for metastatic RCC,
irrespective of risk category. Preliminary Assessment of
Safety of the Expanded Access Trial showed that Response
Rate and Adverse Events rate are not influenced evenly con-
sidering risk factors such as brain metastasis, non-clear-cell
histology, poor PS and elder age.
With two approved multikinase inhibitors, it is important
to determine the cross-resistance between these agents. So
far it appears that cross-resistance is not complete and objec-
tive responses and meaningful disease stabilisation are seen
when the second multikinase inhibitor (sorafenib or suniti-
nib) is employed. Absolute resistance to both agents is, in fact,
uncommon, and was seen in only 7% of patients in one
report.163. mTOR inhibitors
All mRNAs are not equally created; those with long structured
5-untranslated regions, often associated with growth and
cell-cycle regulatory genes (e.g. those encoding c- Myc, cyclin
D1), are poorly translated into protein unless stimulated by
growth factor signalling.17 Akt, MAPK and mTOR are critical
components in this regulation. In at least one form of hered-
itary RCC, resulting from mutations in the TSC1/2 complex,
the mTOR pathway is constitutively activated.18 Mutations
in the tumour suppressor gene phosphatase and tensin
homologue deleted on chromosome ten (PTEN), which occur
in approximately 5% of RCCs and are associated with ad-
vanced-stage aggressive disease, also activate mTOR.19 VHL
loss-of-function mutations lead to HIF and VEGF accumula-
tion. In addition to proteasome-mediated destruction, HIF is
also regulated at the level of protein translation initiation,
which is controlled by mTOR, thus reinforcing the strong
rationale for mTOR inhibitors in RCC.3.1. Temsirolimus
Temsirolimus is a water-soluble ester of sirolimus amenable
to i.v. infusion. Major side-effects associated with temsiroli-
mus are rash and stomatitis.20 In a phase II study21, 111 pa-
tients were treated with varying doses of temsirolimus.
Response rate was 7% (including one CR), median time to
40 E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 3 8 –4 1tumour progression was 5.8 months and median survival
time was 15 months. Interestingly, no dose–response effect
was observed, and the lowest dose was chosen for a subse-
quent phase III trial. A large, international trial randomised
626 previously untreated RCC patients with poor prognostic
features (the majority were high risk patients in the MSKCC
classification) to receive treatment with IFN, temsirolimus,
or the combination, which used a lower dose of temsirolimus.
Although there were no significant differences in response
rates (i.e. 4.8%, 8.6% and 8.1%, respectively), temsirolimus
alone, but not the combination, was superior to single-agent
IFN in terms of the PFS (5.5 versus 3.1 months) and overall
survival (10.9 versus 7.3 months) times. Temsirolimus was
also the safest of the three treatments, having the lowest
rates of grade 3 and 4 toxicities.22 That trial led to the recent
approval of temsirolimus for the treatment of advanced RCC
in the US Although its benefit was demonstrated in patients
with poor prognostic features, its regulatory approval was
not restricted to this subgroup of patients.
3.2. Guidelines indications
Both NCCN and EAU guidelines give an indication of sunitinib
as first-line therapy of mRCC (grade of recommendation 1A).
This assignment is justified for the results of the randomised
phase III trial of sunitinib versus IFN. New data presented at
2007 ASCO Congress show a reduction in the risk of statisti-
cally significant progression of 47% for sunitinib arm and a
PFS of 11 versus 5.1 months of interferon arm. EAU guidelines
in high risk group give an indication of temsirolimus as first-
line therapy (grade of recommendation 1A) by the results of
the trial published in 2007. Anyway in the sunitinib random-
ised phase III trial, the high risk subgroup (3 or more risk fac-
tors), obtained a reduction in risk of progression of 61% versus
IFN, with a median PFS of 10 versus 2 months.
According to EAU guidelines sorafenib has no indication as
first-line treatment, whilst according to NCCN it can be used
with a grade of recommendation 2A.
The association bevacizumab and IFN (AVOREN trial) gives
a reduction in the risk of progression of 37% with a PFS of 10.2
versus 5.4 months of the interpheron arm, and a 70% of con-
trol of disease. Both EAU and NCCN guidelines do not give
indication for the first-line therapy to this association with
grade of recommendation 1, probably because the results of
the trial did not have a critical review by a external commit-
tee, and the missed prospectic evaluation of QoL.
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